COVID-19 mortality among selective serotonin reuptake inhibitor users: author's reply
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Standard
COVID-19 mortality among selective serotonin reuptake inhibitor users : author's reply. / Stauning, Marius Ahm; Gür, Dogukan Jesper; Torp-Pedersen, Christian; Tingleff, Jens.
I: Clinical Microbiology and Infection, Bind 30, Nr. 6, 2024, s. 838-839.Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - COVID-19 mortality among selective serotonin reuptake inhibitor users
T2 - author's reply
AU - Stauning, Marius Ahm
AU - Gür, Dogukan Jesper
AU - Torp-Pedersen, Christian
AU - Tingleff, Jens
PY - 2024
Y1 - 2024
N2 - To the Editor,We have read the letter by Rus and Kooij [1] regarding our study of COVID-19-related mortality among selective serotonin reuptake inhibitor (SSRI) users with great interest and we thank Rus and Kooij for their interest in our study [1,2]. The main claim by Rus and Kooij [1] is that psychiatric comorbidity and lifestyle factors could contribute to residual confounding in our study. These limitations are already acknowledged and discussed in our article, but we appreciate the opportunity to explain our considerations in further detail [2]. It is difficult for us to go into detail with the long list of psychiatric conditions mentioned by Rus and Kooij, as the references citated by Rus and Kooij only cover a few and often severe degrees of the conditions [1]. When performing our study, we had thorough considerations regarding psychiatric comorbidity and identified psychotic disorders and mood disorders as relevant conditions with solid evidence in the literature. However, when keeping the indication and prescription practice of SSRI medications in mind, we found it best only to incorporate adjustment of psychotic disorders in our analysis.
AB - To the Editor,We have read the letter by Rus and Kooij [1] regarding our study of COVID-19-related mortality among selective serotonin reuptake inhibitor (SSRI) users with great interest and we thank Rus and Kooij for their interest in our study [1,2]. The main claim by Rus and Kooij [1] is that psychiatric comorbidity and lifestyle factors could contribute to residual confounding in our study. These limitations are already acknowledged and discussed in our article, but we appreciate the opportunity to explain our considerations in further detail [2]. It is difficult for us to go into detail with the long list of psychiatric conditions mentioned by Rus and Kooij, as the references citated by Rus and Kooij only cover a few and often severe degrees of the conditions [1]. When performing our study, we had thorough considerations regarding psychiatric comorbidity and identified psychotic disorders and mood disorders as relevant conditions with solid evidence in the literature. However, when keeping the indication and prescription practice of SSRI medications in mind, we found it best only to incorporate adjustment of psychotic disorders in our analysis.
U2 - 10.1016/j.cmi.2024.02.022
DO - 10.1016/j.cmi.2024.02.022
M3 - Comment/debate
C2 - 38431254
AN - SCOPUS:85189659971
VL - 30
SP - 838
EP - 839
JO - Clinical Microbiology and Infection
JF - Clinical Microbiology and Infection
SN - 1198-743X
IS - 6
ER -
ID: 388871268